These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 11568739)

  • 1. Quantification of the efficacy of botulinum toxin type A by digital image analysis.
    Heckmann M; Schön-Hupka G
    J Am Acad Dermatol; 2001 Oct; 45(4):508-14. PubMed ID: 11568739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eyebrow height after botulinum toxin type A to the glabella.
    Carruthers A; Carruthers J
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S26-31. PubMed ID: 17241411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An in vivo analysis of the effect and duration of treatment with botulinum toxin type A using digital image speckle correlation.
    Bhatnagar D; Conkling N; Rafailovich M; Phillips BT; Bui DT; Khan SU; Dagum AB
    Skin Res Technol; 2013 Aug; 19(3):220-9. PubMed ID: 23565582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region.
    Rzany B; Ascher B; Fratila A; Monheit GD; Talarico S; Sterry W
    Arch Dermatol; 2006 Mar; 142(3):320-6. PubMed ID: 16549707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The results of periorbital rejuvenation with botulinum toxin A using two different protocols.
    Lee CJ; Kim SG; Han JY
    Aesthetic Plast Surg; 2006; 30(1):65-70. PubMed ID: 16404647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dermal and epidermal remodeling using botulinum toxin type A for facial, non reducible, hyperkinetic lines: two case studies.
    Bowler PJ
    J Cosmet Dermatol; 2008 Sep; 7(3):241-4. PubMed ID: 18789065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New indications for botulinum toxin type A in treating facial wrinkles of the mouth and neck.
    Spósito MM
    Aesthetic Plast Surg; 2002; 26(2):89-98. PubMed ID: 12016492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term prospective follow-up of botulinum toxin treatment for facial rhytides.
    Bulstrode NW; Grobbelaar AO
    Aesthetic Plast Surg; 2002; 26(5):356-9. PubMed ID: 12432474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subjective rating of cosmetic treatment with botulinum toxin type A: do existing measures demonstrate interobserver validity?
    Conkling N; Bishawi M; Phillips BT; Bui DT; Khan SU; Dagum AB
    Ann Plast Surg; 2012 Oct; 69(4):350-5. PubMed ID: 22964674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blind multicenter study of the efficacy and safety of injections of a commercial preparation of botulinum toxin type A reconstituted up to 15 days before injection.
    Hexsel D; Rutowitsch MS; de Castro LC; do Prado DZ; Lima MM
    Dermatol Surg; 2009 Jun; 35(6):933-9; discussion 940. PubMed ID: 19397645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of depression with botulinum toxin A: a case series.
    Finzi E; Wasserman E
    Dermatol Surg; 2006 May; 32(5):645-9; discussion 649-50. PubMed ID: 16706759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study.
    Harden RN; Cottrill J; Gagnon CM; Smitherman TA; Weinland SR; Tann B; Joseph P; Lee TS; Houle TT
    Headache; 2009 May; 49(5):732-43. PubMed ID: 19178577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new technique applying botulinum toxin in narrow and wide foreheads.
    Ozsoy Z; Genc B; Gözü A
    Aesthetic Plast Surg; 2005; 29(5):368-72. PubMed ID: 16151661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study.
    Fagien S; Cox SE; Finn JC; Werschler WP; Kowalski JW
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S2-9. PubMed ID: 17241410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Botulinum toxin A in the treatment of the wrinkles in the upper third of the face].
    Gassia V
    Ann Dermatol Venereol; 2008 Feb; 135 Suppl 3():S175-80. PubMed ID: 18342124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxins for facial wrinkles: beyond glabellar lines.
    Dayan SH; Maas CS
    Facial Plast Surg Clin North Am; 2007 Feb; 15(1):41-9, vi. PubMed ID: 17317554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clostridium botulinum type A toxin for the treatment of upper face animation lines: an Iranian experience.
    Farahvash MR; Arad S
    J Cosmet Dermatol; 2007 Sep; 6(3):152-8. PubMed ID: 17760691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment.
    Rubin MG; Dover J; Glogau RG; Goldberg DJ; Goldman MP; Schlessinger J
    J Drugs Dermatol; 2009 May; 8(5):439-44. PubMed ID: 19537366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin type A treatment of multiple upper facial sites: patient-reported outcomes.
    Carruthers J; Carruthers A
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S10-7. PubMed ID: 17241408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter?
    Carruthers A; Carruthers J; Cohen J
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S97-104. PubMed ID: 17241422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.